Modelling the impact of protein-kinase R allelic variant on HIV biomarkers trajectories by means of latent class mixed models.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 11 2022
03 11 2022
Historique:
received:
06
06
2022
accepted:
28
10
2022
entrez:
4
11
2022
pubmed:
5
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
This paper is based on a retrospective longitudinal study on people living with HIV under antiretroviral treatment (ART) where allelic variants (either heterozygous CT genotype or homozygous CC genotype) have been evaluated at position -168 of the promoter region of the protein kinase R (-168/PKR). In general, antiviral effects of interferon are partially mediated by a RNA-dependent protein kinase (PKR) that, once activated, inhibits protein synthesis. Indeed, activation of PKR response can inhibit HIV replication. To explore the role of allelic variants in shaping dynamics of commonly monitored HIV biomarkers, CD4 cells, CD8 cells and HIV-load were modelled within a latent class mixed model (LCMM) to account for participants' heterogeneity over time. The estimated models identified two sub-groups from CD4 and HIV-load dynamics, revealing better outcomes for subgroups of participants with the heterozygous CT genotype. Heterozygous CT subjects in one of the two identified subgroups exhibited higher increase of CD4 cells and more marked decrease of HIV-load, over time, with respect to the homozygous CC subjects assigned to the same group.
Identifiants
pubmed: 36329104
doi: 10.1038/s41598-022-23289-4
pii: 10.1038/s41598-022-23289-4
pmc: PMC9633692
doi:
Substances chimiques
Biomarkers
0
Antiviral Agents
0
eIF-2 Kinase
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18575Informations de copyright
© 2022. The Author(s).
Références
Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12266-70
pubmed: 15302942
Clin Infect Dis. 2007 Feb 1;44(3):441-6
pubmed: 17205456
Immunol Rev. 2000 Oct;177:99-111
pubmed: 11138790
J Biol Chem. 1993 Apr 15;268(11):7603-6
pubmed: 8096514
J Clin Invest. 2021 Jun 1;131(11):
pubmed: 34060478
Nat Med. 2003 Jul;9(7):839-43
pubmed: 12835701
Annu Rev Med. 2011;62:141-55
pubmed: 21090961
N Engl J Med. 1995 Jan 26;332(4):209-16
pubmed: 7808486
J Exp Med. 1997 May 5;185(9):1681-91
pubmed: 9151905
Semin Cell Biol. 1994 Dec;5(6):417-26
pubmed: 7711290
Lancet. 1992 Oct 10;340(8824):863-7
pubmed: 1357294
AIDS Behav. 2013 May;17(4):1478-87
pubmed: 23553345
AIDS Care. 2009 May;21(5):575-82
pubmed: 19444665
Patient Prefer Adherence. 2022 Jan 07;16:41-49
pubmed: 35027822
Clin Infect Dis. 2005 Sep 1;41(5):713-20
pubmed: 16080095
J Biol Chem. 1997 Dec 5;272(49):30603-6
pubmed: 9388191
Science. 1996 Sep 27;273(5283):1856-62
pubmed: 8791590
J Interferon Res. 1992 Aug;12(4):241-8
pubmed: 1385552
HIV Med. 2020 Dec;21(11):701-707
pubmed: 33369034
AIDS. 2013 Nov 13;27(17):2725-34
pubmed: 23921611
Curr Opin Immunol. 2009 Aug;21(4):414-7
pubmed: 19500967
PLoS One. 2020 Sep 17;15(9):e0236320
pubmed: 32941433
Genes Immun. 2003 Sep;4(6):411-9
pubmed: 12944978
J Interferon Cytokine Res. 1997 Sep;17(9):503-24
pubmed: 9335428
AIDS. 2014 Feb 20;28(4):577-87
pubmed: 24468998
Ann Intern Med. 1997 Nov 15;127(10):882-90
pubmed: 9382366
J Infect Dis. 2005 Sep 15;192(6):992-1002
pubmed: 16107951